Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract